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Introduction: The search for non-invasive diagnostic methods of 
lung cancer (LC) has led to new avenues of research, including the 
exploration of the exhaled breath. Previous studies have shown that 
LC can, in principle, be detected through exhaled-breath analysis. 
This study evaluated the potential of exhaled-breath analysis for the 
distinction of benign and malignant pulmonary nodules (PNs).
Methods: Breath samples were taken from 72 patients with PNs 
in a prospective trial. Profiles of volatile organic compounds were 
determined by (1) gas chromatography/mass spectrometry (GC-
MS) combined with solid-phase microextraction and (2) a chemical 
nanoarray.
Results: Fifty-three PNs were malignant and 19 were benign with 
similar smoking histories and comorbidities. Nodule size (mean ± 
SD) was 2.7 ± 1.7 versus 1.6 ± 1.3 cm (p = 0.004), respectively. 
Within the malignant group, 47 were non–small-cell lung cancer 
and six were small-cell lung cancer. Thirty patients had early-stage 
disease and 23 had advanced disease. Gas chromatography/mass 
spectrometry analysis identified a significantly higher concentra-
tion of 1-octene in the breath of LC, and the nanoarray distinguished 
significantly between benign versus malignant PNs (p < 0.0001; 
accuracy 88 ± 3%), between adeno- and squamous-cell carcinomas 
(p < 0.0001; 88 ± 3%) and between early stage and advanced disease 
(p < 0.0001; 88 ± 2%).
Conclusions: In this pilot study, breath analysis discriminated benign 
from malignant PNs in a high-risk cohort based on LC-related vola-
tile organic compound profiles. Furthermore, it discriminated adeno- 
and squamous-cell carcinoma and between early versus advanced 
disease. Further studies are required to validate this noninvasive 
approach, using a larger cohort of patients with PNs detected by 
computed tomography.
Key Words: Lung cancer, Pulmonary nodules, Diagnosis, Breath, 
Nanoarray.
(J Thorac Oncol. 2012;7: 1528-1533)
Lung cancer (LC) is the leading cause of cancer mortal-ity, accounting for 28% of cancer-related deaths.1,2 The 
National Lung Screening Trial demonstrated that LC screen-
ing by low-dose computed tomography (LDCT) scans 
reduced the LC mortality rate by 20%.3 LDCT screening pro-
grams for LC are expected to be launched in many countries 
in the near future so that a dramatic increase in the detec-
tion of pulmonary nodules (PNs) should be anticipated, and 
accordingly, a dramatic increase in invasive procedures, in 
the related morbidity, and the health care costs. To minimize 
the false-positive rate in future LDCT screening programs, 
a complementary biomarker assay technique, which distin-
guishes benign from malignant nodules in a noninvasive and 
cost-effective manner, is needed.
Exhaled volatile organic compounds (VOCs) are 
promising candidates as LC biomarkers.4–13 These VOCs are 
emitted from the membrane of the cancer cells and/or from 
the surrounding microenvironment to the blood stream.6,7,14,15 
The cancer-related changes in the blood chemistry are then 
reflected in measurable changes to the breath through excretion 
via the lungs. Previous studies with either mass spectrometry 
techniques11–13,16 or with arrays of chemical sensors4,5,10,17–20 
have shown that the breath VOC profile of patients with LC 
differs on average from the profile of healthy subjects. However, 
the relationship between breath VOCs and PN features has not 
been studied sufficiently. Here, we perform an explorative 
study to compare benign with malignant PNs, combining 
complementary information from gas chromatography 
with mass spectrometry (GC-MS) and information from 
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chemical nanoarrays. GC-MS allowed the identification and 
quantification of a wide variety of separate breath VOCs, 
whereas the crossreactive chemical nanoarray provided a 
simple-to-use and inexpensive diagnostic tool without insight 
into the nature and composition of the breath VOCs.
PATIENTS AND METHODS
Test Population, Study Design, and 
Collection of Breath Samples
The study was a prospective trial including 72 patients 
attending subspecialty referral clinics at the University of 
Colorado Cancer Center (Aurora, CO) and Denver Veterans 
Affairs Medical Center (Denver, CO) from March 2009 to 
May 2010. The Colorado Institutional Review Board granted 
approval for the study, and the clinical trial was registered 
at Clinicaltrials.gov (registration no. NCT01386203). All 
patients were under investigation for PNs and were recruited 
after written informed consent. The clinical details of the 
study population are given in Table 1.
Alveolar exhaled breath was collected in chemically 
inert Mylar bags (Eco Medics, Duernten, Switzerland) in a 
controlled way after a 3-minute procedure of lung washout as 
described elsewhere9,10,17 and in the Online Data Supplement, 
Section 1.1 (Supplemental Digital Content 1, http://links.lww.
com/JTO/A320). The procedure was designed to avoid ambi-
ent contaminants and nasal entrainment of gas from entering 
the sampling bags. Each subject provided breath of at least one 
Mylar bag of 750 mL. The content of each bag was transferred 
immediately through an offline procedure to a tenax sorbent tube 
(SKC Inc., Eighty Four, PA). All breath samples were tagged 
with a bar code at the collection site. The tubes were stored 
at 4°C in a clean environment. The sorbent tubes were then 
shipped to the labs at Technion-IIT (Haifa, Israel) for analysis 
by both GC-MS and the chemical nanoarray (see below).
Unrelated to the breath sampling, all patients underwent 
clinical investigation including bronchoscopy, wedge resection, 
and/or lobectomy as was required for final diagnosis (Table 1). 
Patients without a definitive histologic diagnosis were followed 
by serial CT imaging, and final diagnosis was reconfirmed in 
August 2011. Nodules that either regressed or remained stable 
over a 24-month period were considered benign.
Breath Samples Analysis and 
Statistical Treatment
In the first phase of this study, the constituent VOCs in 
the breath samples were analyzed using GC-MS as described 
in the Online Data Supplement, Section 1.2 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A320). GC-MS 
chromatograms were analyzed using GC-MS Postrun Analysis 
(version 2.53; Shimadzu Corporations, Duisburg, Germany). 
The data were processed using the open source XCMS package 
(version 1.22.1; http://metlin.scripps.edu/download/), which 
provides mass/charge (m/z) and retention time. Statistical 
tests were performed by SAS JMP, (version 8.0; SAS Institute 
Inc., Cary, NC) for Wilcoxon/Kruskal–Wallis tests.
In the second phase of this study, the breath samples underwent 
a blind test-run with a chemical nanoarray of 18 crossreactive 
sensors, as described in the Online Data Supplement, Section 
1.3 (Supplemental Digital Content 1, http://links.lww.com/JTO/
A320). Two of the sensors were chemiresistors based on random 
networks of single-wall carbon nanotubes with polycyclic aromatic 
hydrocarbons.21–24 The polycyclic aromatic hydrocarbon molecules 
contained a hydrophobic mesogen and were terminated with (1) an 
ether group and with (2) an 2-ethyl-hexane hydrophobic group.21–24  
Sixteen sensors were chemiresistors based on spherical gold 
nanoparticles (GNPs; 3–4 nm core diameter) coated with hexanethiol, 
2-ethylhexanethiol, 3-methyl-1-butanethiol, octadecylamine, 
decanethiol, dodecanethiol, 2-mercaptobenzoazole, 4-methoxy-
toluenethiol, tert-dodecanethiol, 2-amino-4-chlorobenzenethiol, 
2-mercaptobenzimidazole, benzylmercaptan, 2-nitro-4-trifluoro-
methylbenzenethiol, 2-naphthalenethiol, 2-nitro-4-trifluoro-
methylbenzenethiol and 2-mercaptobenzoazole. The wide variety 
of these crossreactive organic ligands assured responses from a 
wide spectrum of VOCs.4,5,8–10,25 The GNPs were synthesized 
as described by Dovgolevsky et al.26
Wilcoxon test was applied to identify the features that 
show statistically significant differences of the average sensing 
signals for the different study groups. Data classification was 
attempted by employing Discriminant Factor Analysis (DFA).27 
The accuracy of DFA was further confirmed by employ-
ing leave-one-out cross-validation. Statistically significant 
TABLE 1. Clinical Characteristics of the Tested Patients
Benign Nodules 
(n = 19)
Malignant Nodules 
(n = 53)
p (<0.05)
Age (yrs) 60.8 ± 6.8 64.9 ± 7.2 0.038
BMI (kg/m2) 26.2 ± 5.1 27.4 ± 7.2 NS
Males 15 (79%) 31 (58%) NS
Active Smokers 6 (32%) 19 (36%) NS
Former Smokers 11 (58%) 26 (49%) NS
Never Smokers 2 (11%) 8 (15%) NS
PY (total) 40.6 ± 34.4 40.5 ± 27.0 NS
COPD 10 (52%) 26 (49%) NS
IHD 7 (37%) 22 (42%) NS
Nodule size (cm) 1.56 ± 1.3 2.7 ± 1.7 0.004
Diagnostic procedure
 Bronchoscopy 16 20
 Wedge/lobectomy 3 33
Etiology Noncancerous: 13
Atypical Alveolar 
Hyperplasia: 1
Infectious/
Inflammation: 5
NSCLC: 47
Adenocarcinoma: 30
Squamous: 13
Large Cell: 2
Poorly Diff: 2
SCLC: 6
Stage NSCLC
Stage I: 23
Stage II: 4
Stage III: 10
Stage IV: 10
SCLC
Limited: 3
Extensive: 3
BMI, body mass index; PY, pack years; COPD, chronic obstructive pulmonary 
disease; IHD, ischemic heart disease; NS, no significant changes between the groups 
were identified.
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differences between the first-discriminant scores were stud-
ied using the Wilcoxon test. Sensitivity, specificity, and accu-
racy were calculated through leave-one-out cross-validation. 
Statistical tests were performed by SAS JMP, version 8.0.
RESULTS
Seventy-two patients with PNs were examined by GC-MS 
and/or the chemical nanoarray. Baseline epidemiology, smoking 
history, and comorbidities were similar in both groups. The two 
subpopulations were relatively well-matched with respect to their 
ages: 64.9 ± 7.2 years for the malignant nodules versus 60.8 ± 
6.8 years for the benign nodules (p = 0.038). Thirty-six patients 
underwent bronchoscopy and 36 underwent a surgical procedure. 
Nineteen patients had benign findings and 53 had cancer. Forty-
seven patients had non–small-cell lung cancer (NSCLC) (30 
adenocarcinomas, 13 squamous cell carcinoma, 2 large cell carci-
noma, and 2 poorly differentiated carcinoma) and six patients had 
small-cell lung cancer (SCLC). Thirty patients had early-stage 
disease (stage I–II or limited SCLC) and 23 had advanced disease 
(stage III/IV or extensive SCLC; Table 1). Among the benign 
group (n = 19), histological examination identified 13 patients 
with granulomas or fibrotic tissue, one with alveolar hyperplasia, 
and five with infectious/inflammatory histologies. Nodule size 
was significantly higher in the malignant group (mean diameter 
± SD = 2.7 ± 1.7 for LC versus 1.56 ± 1.3 cm for benign, p = 
0.004). Because of the relatively small number of samples, the 
results of this study could be validated only using leave-one-out 
cross-validation. Blinded external validation in an independent 
validation set is the next step to study this approach in the future.
Chemical Analysis of Breath Samples
In the first phase of this study, we identified the VOCs 
that could serve as potential biomarkers for PNs and deter-
mined their relative compositions, using GC-MS in conjuga-
tion with solid-phase microextraction (SPME). Thirty-nine 
samples were analyzed, of which 28 were malignant (25 
NSCLC and 3 SCLC) and 10 were benign. Tumor size was 
2.7 ± 1.7 cm for the malignant versus 1.56 ± 1.3 for the benign 
(p = 0.004). GC-MS analysis identified approximately 200 
VOCs with main masses in the range of 33 to 282 m/z and 
retention times between 1.8 and 42.8 minutes. Nonparametric 
Wilcoxon/Kruskal–Wallis tests identified one VOC that 
appeared in higher concentrations in LC patients than in 
patients with benign nodules (Fig. 1 and Table 2). This VOC 
was 1-octene (Chemical Abstracts Service number: 111-66-0; 
p = 0.049);a see refs. (11,12,28). Comparative GC-MS analy-
sis failed to show any discrimination between early-stage and 
advanced disease of the NSCLC patients and also for subhis-
tologies of NSCLC. Comparative GC-MS analysis was not 
performed for the NSCLC and SCLC groups because of the 
insufficient number of the GC-MS samples of the SCLC group.
Nanoarray Analysis of Breath Samples
In the second phase of the study, 69 breath samples were 
exposed to the chemical nanoarray. Of the 69 samples, 50 
were malignant (45 NSCLC and 5 SCLC) and 19 were benign. 
One of the five SCLC samples was excluded from the analysis 
with the chemical nanoarray because of technical failures of 
the electrical readout of the sensing signals during the analy-
sis. All sensors responded rapidly and reversibly and provided 
a consistent output that is specific to a given breath exposure.
The feasibility of the tailor-made nanoarrays to distin-
guish between the collective VOC patterns of malignant and 
benign lung nodules was demonstrated by building a DFA 
model27 based on the 68 breath samples collected for the chemi-
cal nanoarray. The chemical nanoarray analysis discriminated 
well between the patients with malignant nodules and the 
patients with benign nodules (Fig. 2A). Full separation was 
achieved along the first canonical score (p < 0.0001). Leave-
one-out cross-validation was performed to check the accuracy 
of the DFA model. The first DFA model had a classification suc-
cess of 86% ± 4% for sensitivity, 96% ± 4% for specificity, and 
88% ± 3% for accuracy (Table 3). Receiver operating charac-
teristic analysis has yielded area under the curve of 0.986 (Fig. 
2B; Table 3) for the discrimination between benign and malig-
nant conditions. The identification of the collective patterns was 
a  The mechanism leading to altered production of the 1-octene in the exhaled 
breath of patients with malignant and benign tumors is not clear. However, 
it has been shown that hydrocarbons undergo oxidation by the cytochrome 
P450-associated enzyme activity. These enzymes play a central role in the 
metabolic activation of various xenobiotics, and lead to changes in gene 
expression or enzyme activity in cases of LC, which, in turn, might affect 
the concentration of 1-octene and similar compounds in the body.
FIGURE 1. One potential biomarker for differentiating 
malignant lung nodules from benign ones found by means 
of gas chromatography with mass spectrometry . 1-octene 
shows a statistically significant difference in the peak area of 
the benign and malignant samples (p = 0.0486). The posi-
tions of the mean values for benign and malignant states are 
marked with □, the boxes correspond to their 95% confi-
dence limits, and the error bars correspond to the SD.
TABLE 2. Breath VOC that Showed a Significant  
Statistical Difference in Benign and Malignant Nodules 
(N=38; Malignant = 28; Benign =10)
Retention time  
(min)
m/z Tentative Name Trend in Cancer p*
11.18 83 1-Octene Up 0.049
*Wilcoxon nonparametric method.
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supported by the observation of statistically significant differ-
ences between the subpopulations in the average composition of 
the exhaled breath. Similarly, the chemical nanoarray analysis 
discriminated well between groups of LC patients with different 
subhistology. As seen in Figure 3, excellent distinction could be 
achieved between adeno- and squamous cell carcinomas within 
the test group with malignant nodules. The two subpopulations 
were completely separated along the first canonical score, with 
no overlap between the clusters (p < 0.0001). Cross-validation 
of the analysis yielded an accuracy of 88% ± 3% (Table 3).
Within the NSCLC group, excellent distinction could 
be achieved between early and advanced stages of NSCLC 
(p < 0.0001; Fig. 4). Cross-validation of the analysis yielded 
86% ± 3% sensitivity, 88% ± 6% specificity, and 88% ± 2% 
accuracy (Table 3).
DISCUSSION
Previous studies with exhaled breath have compared LC 
patients with chronic obstructive pulmonary disease patients 
or with healthy subjects, with either GC-MS9,10,12,13 or chemical 
sensors.4,5,9,10,18,20 In contrast, this study used both techniques 
and compared exhaled breath of patients with either malignant 
or benign (>10 mm) PNs that were validated either through 
histological examination or through follow-up serial imaging. 
The results of this study showed that exhaled-breath testing 
might have future potential for the management of patients 
with PNs. In particular, the results indicate that the breath 
testing could be used to discriminate between benign and 
malignant PNs detected by CT, reduce the false-positive rate, 
minimize the risk of morbidity related to invasive diagnostic 
procedures, and reduce the costs of LC screening.
In general, GC-MS yields a wealth of information for 
basic research.9,10,12,13,18 However, this method has several prom-
inent disadvantages for use as a clinical point-of-care applica-
tion. First and foremost, it requires sophisticated, expensive, 
and bulky equipment that would only be available in large, 
well-equipped laboratories. Second, the interpretation of the 
GC-MS results is challenging and requires much expertise. 
Third, the analysis of breath VOCs at part per billion by vol-
ume (ppbv) to part per trillion by volume (pptv) concentrations 
requires preconcentration before GC-MS—for example, onto 
solid-phase microextraction fibers or other suitable absorption 
media.29 The preconcentration methods selectively enhance 
the signals of certain VOCs while potentially missing others. 
These disadvantages were expressed, among the rest, in the fail-
ure of the GC-MS analysis to detect altered VOC production 
between early-stage and advanced NSCLC cases and between 
the NSCLC subhistologies through exhaled-breath samples 
(Table 3), in contrast to our recent in vitro observations of 
similar (sub)histologies.14 As a matter of fact, we have recently 
collected and analyzed headspace samples from cell lines with 
different (sub-)histologic characteristics.14 Statistical analysis 
has identified three substances (decanal, acetophenone, and 
1,3-bis (1,1-dimethylethyl)-benzene) as main contributors to 
the separation between in vitro NSCLC from SCLC with 100% 
sensitivity and 75% specificity.14 Nine VOCs (2 aldehydes, 1 
alkane, 2 ketones, 1 alcohol, and 3 benzene derivatives) showed 
FIGURE 2. Graphical representation of the first canonical 
score values for patients with benign nodules and malig-
nant nodules that were obtained from a chemical nanoarray 
containing 5-nm gold nanoparticle sensors and an organi-
cally functionalized carbon nanotube sensor. A, Each point 
represents one patient. The positions of the mean values are 
marked with □, the boxes correspond to the 95% confidence 
limits, and the error bars correspond to the SDs. The confi-
dence intervals are significantly separated (p < 0.0001). B, 
Receiver operating characteristic curve for the discrimination 
between malignant and benign pulmonary nodules (PNs), 
AUC 0.986. AUC, area under the curve.
TABLE 3.  Sensitivity, Specificity and Accuracy of the 
Chemical Nanoarray (from Leave-One-Out Cross-Validation) 
and the AUC of the ROC Curve Analysis
Sensitivity 
(%)
Specificity 
(%)
Accuracy 
(%)
ROC 
AUC
Malignant/benign 86 ± 4 96 ± 4 88 ± 3 0.986
Adeno/squamous 92 ± 8 78 ± 7 88 ± 3 0.974
Early/advanced NSCLC 86 ± 3 88 ± 6 88 ± 2 0.961
NSCLC, non–small-cell lung cancer; ROC, receiver operating characteristic; AUC, 
area under the curve.
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differences between the subtypes of NSCLC, viz. between 
adenocarcinoma and squamous cell carcinoma. Among these 
VOCs, we identified 2-ethyl-1-hexanol, 1,3-dimethyl-benzene 
and 1,3-bis (1,1-dimethylethyl)-benzene as key distinguish-
ing VOCs, which are all found at a higher concentration in the 
headspace of adenocarcinoma than in the headspace of squa-
mous cell carcinoma.14 The difference between the breath and 
in vitro observations could be explained, therefore, by one or by 
a combination of the following possible reasons: (1) the VOCs 
emitted from the LC cells could be diluted on their way to the 
exhaled breath so that their final concentration in the breath is 
lower than the GC-MS/SPME limit of detection; (2) the emitted 
VOCs expressed a combination with the environmental (host) 
response, rather than the pure cells metabolism (e.g., inflamma-
tion); and/or (3) the analysis of the breath samples by GC-MS/
SPME was affected by confounding factors (variations in life-
style, culture, geographic, etc.), whereas the in vitro findings 
did not take into account these effects.
For breath analysis to become a clinical reality, the tailor-
made nanoarray reported in this study would be more appropriate. 
First, the chemical nanoarray is significantly smaller, easy to use, 
inexpensive, and can detect VOCs in the presence of water vapor, 
without requiring preconcentration and/or dehumidification 
techniques.4,5,8–10,14,26 Indeed, the nanoarray could differentiate 
between benign and malignant tumors with higher accuracy than 
the GC-MS could. Moreover, the nanoarray could differentiate 
between the subhistologies of LC as well as between the early 
stages and advanced stages of NSCLC, whereas the GC-MS 
could not. The higher detection capabilities of the nanoarray, 
compared with those of the GC-MS, could be attributed to the 
fundamentally different sensing mode of the two methods. The 
chemical nanoarray is broadly crossreactive and responsive to all 
(or part of) the LC-specific VOCs of interest. The responses of the 
chemical nanoarray to a specific VOC at a certain concentration 
differ individually between the constituent (nanoarray) sensors 
because of the chemical diversity of the organic ligands and/or 
nanomaterials used (cf. Online Data Supplement, Section 1.3; 
Supplemental Digital Content 1, http://links.lww.com/JTO/A320). 
However, the signals of the same chemical nanoarray to the mixed 
VOCs that are present in the breath sample are additive, so that 
the overall signal of one sensor stems from a total breath VOCs in 
the ppm level of concentrations. Hence, the sensors’ responses are 
less affected by noise than the detected (sub) ppb concentrations 
of the separate VOCs in the GC-MS/SPME analysis.4,5
Discrimination between subpopulations of NSCLC, that is, 
adeno- versus squamous cell carcinoma via the nanoarray is not 
surprising, as our previous studies showed that this discrimination 
is also robust in the in vitro setting.14 In this study, the nanoarray 
showed a clear discrimination between the adenocarcinomas and 
the squamous cell carcinomas (Fig. 3). This finding might have a 
future potential clinical implication, mainly related to the treatment 
algorithm in advanced LC. In patients with adenocarcinomas 
of the lung, invasive diagnostic procedures are often performed, 
as adenocarcinomas have a high rate of gene alterations with 
related therapies. In addition, our future effort is also directed to 
discriminate between NSCLC and SCLC. It would be reasonable 
to expect a higher quantity and variety of metabolites released 
by the SCLC, because SCLC cells are rapidly dividing cells that 
require more adenosine triphosphate, nucleotides, fatty acids, 
membrane lipids, and proteins.30 This assumption is based on 
our previous report of pronounced differences in the headspace 
atmosphere of SCLC and NSCLC cell lines.14 Neither the 
discrimination between the NSCLC and SCLC nor the distinction 
FIGURE 3. Graphical representation of the first canoni-
cal score values for patients with malignant nodules, which 
 differentiate between adenocarcinoma and squamous cell 
lung cancer, obtained from a chemical nanoarray containing 
gold nanoparticle sensors. Each point represents one patient. 
The positions of the mean values are marked with □, the 
boxes correspond to their 95% confidence limits, and the 
error bars correspond to the SDs. The confidence intervals  
are significantly separated (p < 0.0001).
FIGURE 4. Graphical representation of the first canoni-
cal score values for patients with early-stage or advanced 
non–small-cell lung cancer nodules that were obtained from 
a chemical nanoarray containing seven gold nanoparticle 
sensors and an organically functionalized carbon nanotube 
sensor. Each point represents one patient. The positions of 
the mean values are marked with □, the boxes correspond to 
their 95% confidence limits, and the error bars correspond to 
the SDs. The confidence intervals are significantly separated 
(p < 0.0001).
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of the NSCLC subtypes via breath samples would replace tissue 
histology. However, in many cases, tissue is unreachable and a 
noninvasive tool might help to manage such LC patients.
In summary, this study offers an inexpensive and por-
table tool to further improve the noninvasive-biomarker–based 
investigation of patients who are not candidates for invasive 
procedures or in cases where the tissue is hard to sample. More 
specifically, breath analysis with nanoarray could serve as a pri-
mary and/or a secondary screener for PN-positive patients after 
LDCT, and might avoid delay in performing an invasive inves-
tigation when cancer is suspected, rather than proceeding with 
follow-up imaging. Hence, the recommendation for an inva-
sive procedure can be made immediately with a relatively high 
level of confidence. The reported breath test in this study could 
have significant impact on reducing unnecessary investigation 
and reducing the risk of procedure-related morbidity and costs. 
In addition, it could facilitate faster therapeutic intervention, 
replacing time-consuming clinical follow-up that would eventu-
ally lead to the same intervention. Further studies using a larger 
cohort of patients are underway and will be published elsewhere.
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